At RCC diagnosis, patients with an neutrophil-lymphocyte ratio (NLR) above 3.0 and concomitant hyponatremia had a significant 2.8-fold increased risk of death compared with those who had an NLR of 3.0 or lower and normal sodium levels, a Danish study found.
Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
Updated European Association of Urology guidelines recommend pembrolizumab plus axitinib or ipilimumab plus nivolumab for the first-line treatment of metastatic clear-cell renal cell carcinoma.
In a post hoc analysis of a phase 1 trial, nivolumab treatment was associated with long-term survival in a subset of patients with advanced renal cell carcinoma, melanoma, and non-small cell lung cancer.
Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.
Within the first 2 lines of treatment, patients with metastatic renal cell carcinoma who remain on a drug for at least 3 months have longer overall survival than those who do not, a study found.
Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
One type thermal ablation appeared superior for cT1 a renal cell carcinoma patients.
Use of specific immunomodulatory agents is proposed for those with specific corticosteroid-refractory immune-related cutaneous adverse events (ircAEs) based on results of a retrospective analysis.
Investigators observed no differences in surgery time, blood loss, and hospital stay, with deferred vs upfront cytoreductive nephrectomy.
